logo
Plus   Neg
Share
Email

Evotec, Bayer In New Deal To Develop PCOS Treatment Options - Quick Facts

Evotec AG (EVTCY.PK,EVOTF.PK) announced Thursday a new five-year, multi-target partnership with Bayer AG to develop multiple clinical candidates for the treatment of polycystic ovary syndrome or PCOS.

Under the terms of the agreement, both companies will contribute drug targets and a comprehensive set of high-quality technology platforms to jointly develop innovative treatment options.

Bayer and Evotec will share responsibilities during the pre-clinical development of potential clinical candidates. Bayer will be responsible for any subsequent clinical development and commercialisation.

Under the deal, Evotec will receive 6.5 million euros upfront payment and 10 million euros research payments over five years. In addition, Evotec might be eligible to receive pre-clinical, clinical and sales milestones of potentially over 330 million euros as well as royalties up to low double-digit percentages of net sales.

The strategic alliance will also have access to targets from the recently formed partnership between Evotec and Celmatix, a company engaged in data-driven target discovery focused on fertility and women's health.

In 2012, Bayer and Evotec entered their first strategic five-year, multi-target alliance developing treatment options for endometriosis.

A second research alliance was initiated in 2016 to develop multiple clinical candidates for the treatment of kidney diseases.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Global PC shipments returned to growth in the second quarter of 2020 after seeing a significant decline in the preceding first quarter due to COVID-19 related supply-chain disruptions, according to reports by two research firms. The PC market returned to growth in the quarter as production ramped up and vendors restocked their supplies to near-normal levels. The bankruptcy filing of America's oldest apparel retailer Brooks Brothers has ignited significant interest from potential buyers for the brand. WHP Global and a venture backed by Authentic Brands Group LLC and Simon Property Group, Inc., are reportedly considering bids for the retailer. WHP Global owns the ANNE KLEIN and JOSEPH ABBOUD brands. Sundial Herbal Products has recalled around 65 products, which were misbranded and currently unapproved drugs, the U.S. Food and Drug Administration said in a statement. The recall follows an order by a federal judge in June to stop distributing the company's unapproved new drugs. The affected items include herbal products and dietary supplements.
RELATED NEWS
Follow RTT